Explore the rationale for, and importance of, the first phase 3 study investigating the use of stem cell transplantation with omidubicel, an ex vivo expanded umbilical cord blood stem cell graft to unmanipulated umbilical cord blood transfusion. This activity reviews and interprets the results of the study, translates the data to clinical practice for clinicians who manage patients with hematologic malignancies, and features a short video that provides context and perspective on how this pivotal trial may affect patient care.
Mitchell E. Horwitz, MD
Professor of Medicine
Director, Adult Blood and Marrow Transplant Program